Clinical trial of an aldose reductase inhibitor in diabetic neuropathy.
A single-blind, nonrandomized, placebo crossover clinical trial of an aldose reductase inhibitor, Alrestatin (AY 22, 284) was performed over a 4-mo period in nine patients with diabetic peripheral neuropathy. Most patients had subjective benefit, but objective measures of conduction were essentially unchanged. Substantial toxicity was evident, particularly photosensitive skin rash.
D000200:Action Potentials; D000328:Adult; D000368:Aged; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D005260:Female; D006027:Glycosides / Q000032:analysis; D006441:Hemoglobin A / Q000031:analogs & derivatives / Q000032:analysis; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons / Q000502:physiology; D009132:Muscles / Q000294:innervation / Q000503:physiopathology; D010919:Placebos; D013401:Sugar Alcohol Dehydrogenases / Q000037:antagonists & inhibitors*
D006027:Glycosides; D007546:Isoquinolines; D010919:Placebos; C016212:alrestatin; D006441:Hemoglobin A; D013401:Sugar Alcohol Dehydrogenases; D000449:Aldehyde Reductase